Analyst Price Target is $56.33
▲ +69.53% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Agios Pharmaceuticals in the last 3 months. The average price target is $56.33, with a high forecast of $75.00 and a low forecast of $46.00. The average price target represents a 69.53% upside from the last price of $33.23.
Current Consensus is
Moderate Buy
The current consensus among 8 contributing investment analysts is to moderate buy stock in Agios Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More